Investor mix
12 investors on record; lead investors include Gates, Arch Venture Partners, Lilly Asia Ventures, Merck; 3 have since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 3 | 25% |
| Private equity | 2 | 17% |
| Other / undisclosed | 7 | 58% |
Designing technologies to accelerate biotherapeutic development and to reduce manufacturing costs
12 investors on record; lead investors include Gates, Arch Venture Partners, Lilly Asia Ventures, Merck; 3 have since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 3 | 25% |
| Private equity | 2 | 17% |
| Other / undisclosed | 7 | 58% |